Ibritumomab Tiuxetan

Summary

Ibritumomab Tiuxetan (CHEMBL1201606) is a phase-3 clinical-stage antibody targeting MS4A1; indicated across 4 conditions including neoplasm of mature b-cells and non-hodgkin lymphoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Targets: 1 (MS4A1)
• Indications: 4 conditions
• Clinical trials: 9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201606
Name	Ibritumomab Tiuxetan
Type	Antibody
Max phase	3

Also known as: Ibritumomab tiuxetan, IDEC-129, IDEC-IN2B8, IDEC-Y2B8, IDEC-Y2B8 IDEC-129, IBRITUMOMAB TIUXETAN

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
MS4A1	CD20 (membrane-spanning 4-domains, subfamily A, member 1)	Binding		0%	P11836

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): MS4A1.

Dominant GO biological processes

GO term	Targets
store-operated calcium entry	1
humoral immune response	1
cell surface receptor signaling pathway	1
response to bacterium	1
B cell differentiation	1
B cell proliferation	1
B cell activation	1
B cell receptor signaling pathway	1
protein tetramerization	1
calcium ion import into cytosol	1
positive regulation of calcium ion import across plasma membrane	1

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm of mature B-cells	3	MONDO:0004949	EFO:0000096
non-Hodgkin lymphoma	3	MONDO:0018908	EFO:0005952
follicular lymphoma	3	MONDO:0018906	MONDO:0018906
lymphoma	2	MONDO:0005062	EFO:0000574

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE2	4
PHASE3	3
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00319332	PHASE3	WITHDRAWN	A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
NCT00491491	PHASE3	COMPLETED	Zevalin-beam for Aggressive Lymphoma
NCT02063685	PHASE3	COMPLETED	Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma
NCT00193440	PHASE2	COMPLETED	Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin’s Lymphoma
NCT00372905	PHASE1/PHASE2	TERMINATED	Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma
NCT00453102	PHASE2	COMPLETED	Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma
NCT00662948	PHASE2	COMPLETED	ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)
NCT01811368	PHASE2	UNKNOWN	Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
NCT00392691	PHASE1	COMPLETED	Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin’s Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).